论文部分内容阅读
对６５例胃粘膜异型增生和５４例胃癌进行免疫组化研究，结果显示Ⅰ级（ｎ＝２０）、Ⅱ级（ｎ＝２０）异型增生无ｃ－ｅｒｂＢ－２和ｐ５３蛋白表达，Ⅲ级（ｎ＝２５）中表达ｃ－ｅｒｂＢ－２７例（２８．０％）、ｐ５３８例（３２．０％）；胃癌中ｃ－ｅｒｂＢ－２阳性Ⅰ级６０．０％（１２／２０）、Ⅱ级４２．９％（６／１４）、Ⅲ级２５．０％（５／２０），Ⅰ～Ⅱ级癌的ｃ－ｅｒｂＢ－２阳性率与Ⅲ级比较差异有显著性（χ２＝４．０４，Ｐ＜０．０５），ｐ５３蛋白阳性Ⅰ级９０．０％（１８／２０）、Ⅱ级５０．０％（７／１４）、Ⅲ级４５．０％（９／２０），Ⅰ～Ⅱ级癌ｐ５３蛋白阳性率与Ⅲ级比较差异有显著性（χ２＝４．３８，Ｐ＜０．０５）。结果提示ｃ－ｅｒｂＢ－２和ｐ５３基因突变均发生于胃粘膜癌变的后期。
An immunohistochemical study of 65 cases of gastric dysplasia and 54 cases of gastric cancer revealed no expression of c-erbB-2 and p53 protein in Grade I (n=20), Grade II (n=20) dysplasia, and Grade III ( C-erbB-27 was expressed in n=25) cases (28.0%) and p538 cases (32.0%); c-erbB-2 positive in grade I gastric cancer was 60.0% (12/20), grade II 42.9% (6/14), grade III 25.0% (5/20), and the positive rate of c-erbB-2 in grades I-II cancer was significantly different from grade III (χ2=4.04, P<0.05), p53 protein positive class I 90.0% (18/20), class II 50.0% (7/14), class III 45.0% (9/20), class I-II The positive rate of p53 protein in cancer was significantly different from that in grade III (χ2=4.38, P<0.05). The results suggest that c-erbB-2 and p53 gene mutations occur in the late stages of gastric cancer.